{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:23:22Z","timestamp":1771842202654,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Our aim was to investigate the newest generation anti-cyclic citrullinated peptide (CCP) antibody 3.1 assay in diagnosing rheumatoid arthritis (RA) compared with other autoimmune and non-autoimmune diseases. We performed a retrospective observational chart review of patients with a positive CCP level over a one-year period at a single academic institution and assessed the associated diagnoses after at least six-months of follow-up. Of the 281 CCP positive patients during that period, 48% had a diagnosis of RA. The positive predictive value of RA in patients with a high CCP 3.1 assay was 0.619 compared to 0.248 with a low positive CCP 3.1 assay (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001). Overall, there was a lower than expected positive predictive value of CCP 3.1 level with an RA diagnosis, though the likelihood of having an RA diagnosis was higher with a higher CCP level.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025558","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T13:30:46Z","timestamp":1619011846000},"page":"e25558","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-0432","authenticated-orcid":false,"given":"James J.","family":"Son","sequence":"first","affiliation":[{"name":"Department of Internal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ishimori","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mirocha","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Weisman","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsy J.","family":"Forbess","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","article-title":"Epidemiology of adult rheumatoid arthritis","volume":"4","author":"Alamanos","year":"2005","journal-title":"Autoimmun Rev"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrrheum.2011.76","article-title":"Anti-CCP antibodies: the past, the present and the future","volume":"7","author":"Van Venrooij","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/art.38017","article-title":"Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease","volume":"65","author":"Demoruelle","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12026-013-8425-8","article-title":"Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population","volume":"56","author":"Szekanecz","year":"2013","journal-title":"Immunol Res"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10067-008-0999-5","article-title":"A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis","volume":"28","author":"Dos Anjos","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1373\/clinchem.2007.087569","article-title":"Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins","volume":"53","author":"Bizzaro","year":"2007","journal-title":"Clin Chem"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cca.2014.07.032","article-title":"Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies","volume":"437","author":"Webb","year":"2014","journal-title":"Clin Chim Acta"},{"key":"R8-20250504","first-page":"1002","article-title":"Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides","volume":"35","author":"Innala","year":"2008","journal-title":"J Rheumatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cca.2014.05.019","article-title":"Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests","volume":"436","author":"Infantino","year":"2014","journal-title":"Clin Chim Acta"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.2009.108456","article-title":"Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis","volume":"69","author":"Damjanovska","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12016-007-8027-0","article-title":"Diagnostic accuracy of immunoassays for the detection of antibodies to citrullinated proteins","volume":"34","author":"Bizzaro","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.62.9.870","article-title":"Clinical utility of the anti-CCP assay in patients with rheumatic diseases","volume":"62","author":"Lee","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/ard.2004.021477","article-title":"Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sj\u00f6gren's syndrome","volume":"64","author":"Van Noord","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar3237","article-title":"Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis","volume":"13","author":"Kokkonen","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3899\/jrheum.180897","article-title":"Anti-CCP3.1 and Anti-CCP-IgA are associated with increasing age in individuals without rheumatoid arthritis","volume":"46","author":"Berens","year":"2019","journal-title":"J Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:11:13Z","timestamp":1746339073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":15,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025558","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"2020-07-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}